Issue Date: September 19, 2011
Seattle Genetics Signs U.K. Partner
Seattle Genetics and Oxford BioTherapeutics will jointly discover antibody-drug conjugates for cancer. OBT will generate panels of monoclonal antibodies against tumor-specific antigens that will be screened for activity using Seattle Genetics’ technology. The companies will each have an equal number of alternating options to select resulting antibody-drug conjugates for further development. Each company will receive progress-dependent milestone payments and royalties on sales of any resulting products by the other partner.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society